Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 3/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 4/20 | 0.33 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20575666 | 0.86 | LMNA (0.41) | LMNAERN1PRKDCALDH1A3ALDH1A1 | |
| SCHEMBL14292894 | 0.79 | KDM1A (0.39) | KDM1AKDM1BKCNH2GABRA1GABRB2 | |
| SCHEMBL933374 | 0.79 | ERN1 (0.43) | LMNAERN1PRKDCKDM1AKDM1B | |
| SCHEMBL29655114 | 0.79 | ERN1 (0.43) | LMNAERN1PRKDCKDM1AKDM1B | |
| SCHEMBL21358663 | 0.78 | LMNA (0.41) | LMNAERN1PRKDCALDH1A3ALDH1A1 | |
| SCHEMBL3133038 | 0.78 | ALDH1A1 (0.41) | LMNAERN1PRKDCALDH1A3ALDH1A1 | |
| SCHEMBL31477129 | 0.78 | GRIA1 (0.41) | LMNAERN1PRKDCKDM1AKDM1B | |
| SCHEMBL633623 | 0.76 | ERN1 (0.45) | LMNAERN1PRKDCKDM1AKDM1B | |
| SCHEMBL14710706 | 0.75 | KDM1A (0.47) | LMNAKDM1AKDM1BALDH1A1KCNH2 | |
| SCHEMBL15920680 | 0.75 | KDM1A (0.43) | LMNAERN1PRKDCKDM1AKDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-27 | — | — | US | disclosed |
| WO-2018089449-A1 | BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | SLC5A2, SLC5A1, SLC2A2 | LMNA 2950/4885ERN1 3748/4885PRKDC 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.